Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

Background: Increased levels of antibodies to neurofilament light protein (NF-L) in biological fluids have been found to reflect neuroinflammatory responses and neurodegeneration in multiple sclerosis (MS). Objective: To evaluate whether levels of serum antibodies against NF-L correlate with clinica...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2014-09, Vol.20 (10), p.1355-1362
Main Authors: Amor, Sandra, van der Star, Baukje J, Bosca, Isabel, Raffel, Joel, Gnanapavan, Sharmilee, Watchorn, Jonathan, Kuhle, Jens, Giovannoni, Gavin, Baker, David, Malaspina, Andrea, Puentes, Fabiola
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Autoantibodies - blood
Biomarkers - blood
Case-Control Studies
Cross-Sectional Studies
Disability Evaluation
Drug Monitoring - methods
Enzyme-Linked Immunosorbent Assay
Europe
Female
Humans
Immunosuppressive Agents - therapeutic use
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive - blood
Multiple Sclerosis, Chronic Progressive - diagnosis
Multiple Sclerosis, Chronic Progressive - drug therapy
Multiple Sclerosis, Chronic Progressive - immunology
Multiple Sclerosis, Relapsing-Remitting - blood
Multiple Sclerosis, Relapsing-Remitting - diagnosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - immunology
Natalizumab
Neurofilament Proteins - immunology
Predictive Value of Tests
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Increased levels of antibodies to neurofilament light protein (NF-L) in biological fluids have been found to reflect neuroinflammatory responses and neurodegeneration in multiple sclerosis (MS). Objective: To evaluate whether levels of serum antibodies against NF-L correlate with clinical variants and treatment response in MS. Methods: The autoantibody reactivity to NF-L protein was tested in serum samples from patients with relapsing–remitting MS (RRMS) (n=22) and secondary progressive MS (SPMS) (n=26). Two other cohorts of RRMS patients under treatment with natalizumab were analysed cross-sectionally (n=16) and longitudinally (n=24). The follow-up samples were taken at 6, 12, 18 and 24 months after treatment, and the NF-L antibody levels were compared against baseline levels. Results: NF-L antibodies were higher in MS clinical groups than healthy controls and in RRMS compared to SPMS patients (p
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458514521887